基于TGF-β1/Smads通路治疗心肌纤维化的研究进展

Research progress of treatment of myocardial fibrosis based on TGF-β1/Smads pathway

心肌纤维化是全身多种疾病破坏心脏组织和结构的病理表现,可导致最终进展为心力衰竭。因此,抑制心肌纤维化,对于改善心脏结构、保护心脏功能意义重大。影响心肌纤维化的信号通路众多,但转化生长因子(TGF)-β1/Smads信号通路却是影响心肌纤维化的经典通路。近年来,对其抑制心肌纤维化的各种研究非常广泛,本文结合近年来国内外最新发表的相关文献,阐述中西医关于TGF-β1/Smads信号通路治疗心肌纤维化的最新进展,以期提供新的思路与方向。

Myocardial fibrosis is a pathological manifestation of heart tissue and structure destroyed by various diseases throughout the body,which can lead to heart failure.Therefore,inhibiting myocardial fibrosis is of great significance for improving heart structure and protecting heart function.Although there are many signal pathways that affect myocardial fibrosis,the transforming growth factor(TGF)-β1/Smads signaling pathway is a classic pathway that affects myocardial fibrosis.In recent years,various studies on its inhibition of myocardial fibrosis have been very extensive.This article combines the latest related documents published at home and abroad in recent years to explain the latest developments of TGF-β1/Smads signaling pathway in the treatment of myocardial fibrosis in Chinese and Western medicine,in order to provide new ideas and directions.